DCDaniella Coker

Daniella Coker

*This is an algorithmically generated author record based on publicly available information.

Daniella Coker has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Viewing Direct-to-Consumer Genetic Test Results for Depression Risk Is Psychologically Well Tolerated: Evidence from a Longitudinal Equivalence Study

    by Noura S. Abul-Husn, Rebecca M. K. Berns, Devika Dhamija, Michael V. Holmes, Chelsea L. Robertson, Daniella Coker, R. Ryanne Wu, Jingran Wen, 23andMe Research

    Background: Depression is a frequent focus of interest in genetic testing. Despite growing availability of polygenic risk scores (PRS) for depression, little is known about the psychological impact of receiving them in real-world settings. To quantify the impact of receiving an at-risk depression PRS result on depression and anxiety symptoms, we conducted a longitudinal, prospective cohort study of 23andMe, Inc. research participants. Methods: Surveys were conducted between October 19, 2022 and October 9, 2023. Eligible participants were U.S. residents ≥ 18 years old who completed two surveys assessing depression and anxiety symptoms and had an at-risk PRS result for depression (odds ratio ≥ 1.5). We compared individuals who viewed their result to individuals who did not. Primary outcomes were changes in depression (Patient Health Questionnaire-8) and anxiety (Depression Anxiety Stress Scale-21) symptom scores relative to baseline. We fitted linear regressions to model each outcome, adjusting for age, sex, genetic ancestry, income, prior depression and anxiety, and baseline scores. Using an equivalence testing framework, the smallest effect size of interest was defined as Cohen’s d = ±0.5. Findings: We analyzed data from 917 participants, including 361 who viewed the depression PRS and 556 who did not. Score changes from baseline to follow-up were statistically equivalent for individuals who viewed PRS results and those who did not. The adjusted between-group differences in score changes were −0.17 points for depression (90% CI, −0.59–0.24, two one-side tests p < 0.001) and −0.092 points for anxiety (90% CI, −0.35–0.17, two one-side tests p < 0.001), both equivalent within the predefined margin. Results were consistent in substrata defined by presence or absence of prior depression or anxiety. Interpretation: Among genetically at-risk individuals, exposure to a depression PRS result was well-tolerated in a real-world setting. Funding: 23andMe, Inc.

  • Open Access

    A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease

    by Stella Jensen-Roberts, Taylor L. Myers, Peggy Auinger, Paul Cannon, Helen M. Rowbotham, Daniella Coker, Eli Chanoff, Julia Soto, Meghan Pawlik, Katherine Amodeo, et al.

    Background and Objectives To recruit and characterize a national cohort of individuals who have a genetic variant (LRRK2 G2019S) that increases risk of Parkinson disease (PD), assess participant satisfaction with a decentralized, remote research model, and evaluate interest in future clinical trials. Methods In partnership with 23andMe, Inc., a personal genetics company, LRRK2 G2019S carriers with and without PD were recruited to participate in an ongoing 36-month decentralized, remote natural history study. We examined concordance between self-reported and clinician-determined PD diagnosis. We applied the Movement Disorder Society Prodromal Parkinson9s Disease Criteria and asked investigators to identify concern for parkinsonism to distinguish participants with probable prodromal PD. We compared baseline characteristics of LRRK2 G2019S carriers with PD, with prodromal PD, and without PD. Results Over 15 months, we enrolled 277 LRRK2 G2019S carriers from 34 states. At baseline, 60 had self-reported PD (mean [SD] age 67.8 years [8.4], 98% White, 52% female, 80% Ashkenazi Jewish, and 67% with a family history of PD), and 217 did not (mean [SD] age 53.7 years [15.1], 95% White, 59% female, 73% Ashkenazi Jewish, and 57% with a family history of PD). Agreement between self-reported and clinician-determined PD status was excellent (κ = 0.94, 95% confidence interval 0.89–0.99). Twenty-four participants had prodromal PD; 9 met criteria for probable prodromal PD and investigators identified concern for parkinsonism in 20 cases. Compared with those without prodromal PD, participants with prodromal PD were older (63.9 years [9.0] vs 51.9 years [15.1], p < 0.001), had higher modified Movement Disorders Society-Unified Parkinson9s Disease Rating Scale motor scores (5.7 [4.3] vs 0.8 [2.1], p < 0.001), and had higher Scale for Outcomes in PD for Autonomic Symptoms scores (11.5 [6.2] vs 6.9 [5.7], p = 0.002). Two-thirds of participants enrolled were new to research, 97% were satisfied with the overall study, and 94% of those without PD would participate in future preventive clinical trials. Discussion An entirely remote national cohort of LRRK2 G2019S carriers was recruited from a single site. This study will prospectively characterize a large LRRK2 G2019S cohort, refine a new model of clinical research, and engage new research participants willing to participate in future therapeutic trials.


  • Top Cited Papers

    Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity

    by Janie F. Shelton, Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa Filshtein-Sonmez, Daniella Coker, Antony Symons, Jorge Esparza-Gordillo, Stella Aslibekyan, Adam Auton, et al.

    COVID-19 presents with a wide range of severity, from asymptomatic in some individuals to fatal in others. Based on a study of 1,051,032 23andMe research participants, we report genetic and nongenetic associations with testing positive for SARS-CoV-2, respiratory symptoms and hospitalization. Using trans-ancestry genome-wide association studies, we identified a strong association between blood type and COVID-19 diagnosis, as well as a gene-rich locus on chromosome 3p21.31 that is more strongly associated with outcome severity. Hospitalization risk factors include advancing age, male sex, obesity, lower socioeconomic status, non-European ancestry and preexisting cardiometabolic conditions. While non-European ancestry was a significant risk factor for hospitalization after adjusting for sociodemographics and preexisting health conditions, we did not find evidence that these two primary genetic associations explain risk differences between populations for severe COVID-19 outcomes.


  • Open Access

    Trans-ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity

    by Janie F. Shelton, Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa Filshtein-Somnez, Daniella Coker, Antony Symons, Jorge Esparza-Gordillo, Stella Aslibekyan, Adam Auton

    COVID-19 presents with a wide range of severity, from asymptomatic in some individuals to fatal in others. Based on a study of over one million 23andMe research participants, we report genetic and non-genetic associations with testing positive for COVID-19, respiratory symptoms, and hospitalization. Risk factors for hospitalization include advancing age, male sex, elevated body mass index, lower socio-economic status, non-European ancestry, and pre-existing cardio-metabolic and respiratory conditions. Using trans-ethnic genome-wide association studies, we identify a strong association between blood type and COVID-19 diagnosis, as well as a gene-rich locus on chr3p21.31 that is more strongly associated with outcome severity. While non-European ancestry was found to be a significant risk factor for hospitalization after adjusting for socio-demographics and pre-existing health conditions, we did not find evidence that these two primary genetic associations explain differences between populations in terms of risk for severe COVID-19 outcomes.